TICKERNERD
Menu
GILDGILDHealthcare · Drug Manufacturers - General

GILD Stock Forecast: Gilead Sciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$144
−0.75% on the day

The 28 Wall Street analysts covering Gilead Sciences, Inc. hold a median 12-month price target of $160 — +11.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$178.2B
Ticker Nerd rank
93 / 100
Median analyst target
$160
Analysts covering
28
Revenue$7.8B+10.2% y/y
Operating income$2.5B
Net income−$10.5B
Free cash flow$3.4B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.0%
1M
+5.9%
YTD
+18.4%
1Y
+25.0%
From 52W high
−6.7%
From 52W low
+32.3%
$109
$154
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GILD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Gilead Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Value
99
Accruals
98
Quality
96
Revisions
74
Momentum
66
Growth
52
Issuance
50
Size
2

Volatility (100): The share price has been relatively steady.

Issuance (50): The company has been issuing shares or taking on financing, diluting existing holders.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GILD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GILD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$120$140$160$180Oct 25Jan 26Apr 26Jul 26GILDHigh $180Median $160Low $123

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
21 Buy6 Hold1 Sell
Low $123Median $160High $180

The green dot is the last close — the median target sits +11.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCMaintainsBuy$155 → $175
5 Aug 2026Cantor FitzgeraldReiteratesOverweight$155
5 Aug 2026Cantor FitzgeraldReiteratesOverweight—
5 Aug 2026NeedhamReiteratesBuy$170
5 Aug 2026NeedhamReiteratesBuy—
5 Aug 2026RBC CapitalMaintainsSector Perform—
5 Aug 2026RBC CapitalMaintainsSector Perform$120 → $123
29 July 2026BarclaysMaintainsEqual-Weight$155 → $145
29 July 2026BarclaysMaintainsEqual-Weight—
27 July 2026Morgan StanleyMaintainsOverweight$166 → $165
27 July 2026Morgan StanleyMaintainsOverweight—
21 July 2026Leerink PartnersDowngradeMarket Perform—
21 July 2026Leerink PartnersDowngradeMarket Perform$146 → $127
8 July 2026Morgan StanleyMaintainsOverweight—
8 July 2026Morgan StanleyMaintainsOverweight$168 → $166
7 July 2026RBC CapitalMaintainsSector Perform—
7 July 2026RBC CapitalMaintainsSector Perform$122 → $120
7 July 2026Truist SecuritiesMaintainsBuy—
7 July 2026Truist SecuritiesMaintainsBuy$157 → $156
6 July 2026Cantor FitzgeraldReiteratesOverweight$155

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GILD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GILD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Gilead Sciences, Inc. returned +25.0% against +17.5% for the S&P 500, dividends included.

GILD vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Oct 25Jan 26Apr 26Jul 26GILDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GILD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
23
Analysts cutting
1
Fundamentals

Gilead Sciences, Inc. (GILD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.9×

Cheaper than 41% of US stocks

Price / sales
5.9×

Cheaper than 22% of US stocks

Price / book
15.1×

Cheaper than 6% of US stocks

EV / EBITDA
13.7×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
10.2%

Higher than 52% of US stocks

Earnings growth (YoY)
10.2%

Higher than 48% of US stocks

Gross margin
79.8%

Higher than 90% of US stocks

Operating margin
33.7%

Higher than 89% of US stocks

Net margin
−10.6%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−20.7%

Higher than 31% of US stocks

Return on assets
14.1%

Higher than 96% of US stocks

Dividend yield
2.3%

Higher than 51% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Gilead Sciences, Inc. (GILD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Gilead Sciences, Inc. has a market value of $178.2B and an enterprise value of $199.5B.

  • Revenue in the twelve months to 30 June 2026: $30.5B. The latest quarter grew 10.2% year on year.

  • Net income over the same four quarters: −$3.2B, a −10.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.67.

  • Free cash flow in the twelve months to 30 June 2026: $12.9B.

  • Gilead Sciences, Inc. spent $1.4B on share buybacks and $4.1B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.2B.

  • Trailing P/E: 17.9×; forward P/E: 14.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.28%, paying out 43% of earnings.

  • Gilead Sciences, Inc. employs 17,000 people — $1.8M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

GILD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
GILDGilead Sciences, Inc.$178.2B
93
PFEPfizer Inc.$157.6B
78
AMGNAmgen, Inc.$203.4B
90
BMYBristol Myers Squibb Co.$129.6B
99
MRKMerck & Co., Inc.$357.2B
82
ABBVAbbVie, Inc.$454.3B
96
JNJJohnson & Johnson$640.0B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Gilead Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GILD news & analysis

Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Gilead Sciences presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports the company's participation in the conference event.

Why it matters — A GILD watcher would care because the conference presentation transcript offers an opportunity to review management's remarks on the company's strategy and outlook.

Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth

MarketBeat · 10 Sept 2026positive

Gilead Sciences CFO Andy Dickinson spoke at the Cantor Global Healthcare Conference, expressing confidence in continued growth opportunities across the company's HIV prevention and treatment businesses, while also highlighting progress in inflammation, oncology, and cell therapy programs.

Why it matters — The CFO's upbeat outlook signals to investors that Gilead sees sustained long-term growth in its core HIV franchise even as it diversifies into other therapeutic areas.

Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Gilead Sciences presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of its remarks published by Seeking Alpha. The company used the event to address investors during the scheduled conference presentation.

Why it matters — A GILD watcher would care because presentations at this major healthcare conference offer insight into management's current positioning and key themes, which can inform investor perception.

Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode

MarketBeat · 10 Sept 2026positive

Gilead Sciences Chief Medical Officer Dietmar Berger presented the company's priorities across HIV, oncology, and inflammation at a Wells Fargo conference, describing a portfolio expanded through internal development and acquisitions that is now entering a phase of prioritization and execution.

Why it matters — GILD watchers would care because the company's pipeline is transitioning from expansion into a concrete execution phase, signaling momentum across key therapeutic areas like HIV and oncology.

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

Zacks Investment Research · 8 Sept 2026negative

Gilead Sciences (GILD) closed at $146.64, down 2.88% from the previous trading day, a larger drop than that of the general market. The decline was reported by Zacks Investment Research as a key trading insight.

Why it matters — A GILD watcher would care because the stock underperformed the broader market in a single trading session, signaling notable price movement to monitor.

FAQ

Frequently asked questions about GILD stock

What is the GILD stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Gilead Sciences, Inc. have a median 12-month price target of $160, with estimates ranging from $123 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GILD stock a buy right now?

Of the 28 analysts covering Gilead Sciences, Inc., 21 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Gilead Sciences, Inc. 93 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GILD?

As at 12 Sept 2026, Gilead Sciences, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will GILD stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +11.3% from the last close, and Ticker Nerd's factor model ranks Gilead Sciences, Inc. 93 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GILD stock forecast for 2030?

No analyst covering Gilead Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GILD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $123 to $180 over the next 12 months.

How has GILD stock performed over the past year?

Gilead Sciences, Inc. returned +25.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Gilead Sciences, Inc. do?

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases with unmet medical needs.

What is the latest news on GILD?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript". Gilead Sciences presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports the company's participation in the conference event.

Company

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases with unmet medical needs. Gilead Sciences specializes in therapeutic areas including HIV, viral hepatitis, oncology, inflammation, respiratory conditions, and cardiovascular disease. Its current portfolio includes prescription medicines and specialty treatments used in hospitals, clinics, and long-term care settings, supporting patients across global markets. The company also maintains an active pipeline in virology, oncology, and inflammation, reinforcing its role as a major provider of branded therapies in modern healthcare. Headquartered in Foster City, California, Gilead Sciences serves physicians, healthcare systems, and patients through a diversified product portfolio centered on infectious disease and specialty care.

CEO Mr. Daniel P. O'Day · 17,000 employees · United States · https://www.gilead.com